This Cancer Immunotherapy Drug Discovery Outsourcing market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The cancer immunotherapy drug discovery outsourcing market size has grown rapidly in recent years. It will grow from $1.5 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing cases of adverse drug reactions, increasing demand for comprehensive genomic testing, increasing global incidence of cancer, a growing need for targeted therapy, and a growing number of clinical trials.
The cancer immunotherapy drug discovery outsourcing market size is expected to see rapid growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to the rising importance of personalized medicine, increasing diagnostic tests, increasing focus on personalized cancer therapy, increasing healthcare expenditure, and increasing cancer incidence and awareness. Major trends in the forecast period include advancements in diagnostic technologies, next-generation sequencing (NGS), integration of artificial intelligence (AI), liquid biopsy technologies, the development of point-of-care companion diagnostic devices, and innovative testing technologies.
The escalating expenses associated with research and development (R&D) are projected to drive the expansion of the cancer immunotherapy drug discovery outsourcing market. The substantial R&D costs stem from the necessity of specialized expertise, costly equipment, and the inherent risks linked with innovation. The outsourcing of drug discovery activities taps into the economies of scale provided by contract research organizations (CROs), enabling smaller biotech firms and startups to optimize their R&D budgets and allocate resources more efficiently, thereby enhancing cost-effectiveness. For instance, in June 2023, as reported by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the total pharmaceutical R&D expenditure in Europe reached $49.5 billion (€44,500 million) in 2022, marking a rise of around 6.45% from $46.5 billion (€42,533 million) in 2021. Consequently, the exorbitant costs associated with in-house research and development are fueling the growth of the cancer immunotherapy drug discovery outsourcing market.
Key players in the cancer immunotherapy drug discovery outsourcing market are embracing a strategic partnership approach to bolster cancer drug production and gain competitive advantages. Strategic partnerships typically involve collaborative relationships among two or more organizations, pooling their resources, expertise, and efforts to achieve common goals or objectives. For instance, in February 2022, Ono Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, and Bristol-Myers Squibb, a US-based biopharmaceutical company, forged an outsourcing agreement with Prime Research Institute for Medical Research, Inc., a Japan-based research institute, for a joint clinical research project focused on gastric cancer patients treated with Opdivo (nivolumab) in combination with chemotherapy. This collaborative initiative, sponsored by the industry, encompasses a large-scale, multi-institutional study employing PRiME-R's CyberOncology data input support system, facilitating the standardization, structuring, management, and integration of real-world data in routine cancer clinical practice. The clinical research, utilizing CyberOncology, assesses the effectiveness of Opdivo combined with chemotherapy for untreated advanced or recurrent gastric cancer. Involving approximately 30 medical institutions nationwide, the study aims to streamline data input, improve data accuracy, and expedite analysis.
In February 2022, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, entered into a collaboration with Bristol Myers Squibb K.K., a US-based multinational biopharmaceutical company. The partnership aims to conduct a large-scale, multi-institutional clinical research study to assess the efficacy and safety of Opdivo (nivolumab) in combination with chemotherapy for patients with advanced or recurrent gastric cancer. This initiative makes use of PRIMER's CyberOncology system, which standardizes and integrates real-world data from clinical practice, enhancing the accuracy and efficiency of the research process.
Major companies operating in the cancer immunotherapy drug discovery outsourcing market are Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, WuXi AppTec Co Ltd., Charles River Laboratories International Inc., PerkinElmer Inc, Bio-Rad Laboratories Inc, QIAGEN N.V., Evotec SE, Shanghai ChemPartner Co. Ltd., Aragen Life Sciences Limited, GenScript Biotech Corporation, BGI Genomics Co. Ltd., NeoGenomics Laboratories Inc, ARUP Laboratories, Syngene International Limited, BioDuro-Sundia, Ambry Genetics Corporation, Selvita, Crown Bioscience International, CENTOGENE N.V., Jubilant Biosys, Oncodesign Services, Icagen Inc., Reaction Biology Corporation, ChemBridge Corporation.
North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer immunotherapy drug discovery outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cancer immunotherapy drug discovery outsourcing is a specialized service model within the pharmaceutical and biotech sectors. It involves entrusting aspects of cancer immunotherapy drug development to external service providers, typically contract research organizations (CROs) or contract development and manufacturing organizations (CDMOs). This approach accelerates innovation by leveraging external expertise and resources, allowing pharmaceutical companies to concentrate on their core activities.
The primary drug types involved in cancer immunotherapy drug discovery outsourcing include monoclonal antibodies, immunomodulators, oncolytic viral therapies, cancer vaccines, and others. Monoclonal antibodies are laboratory-made molecules that mimic the immune system's ability to target specific proteins on cancer cells, aiding in fighting off harmful pathogens. The services provided encompass target identification and validation, lead screening and characterization, and cell-based assays utilized in therapeutic areas such as lung cancer, breast cancer, melanoma, and others.
The cancer immunotherapy drug discovery outsourcing market research report is one of a series of new reports that provides cancer immunotherapy drug discovery outsourcing market statistics, including cancer immunotherapy drug discovery outsourcing industry global market size, regional shares, competitors with a cancer immunotherapy drug discovery outsourcing market share, detailed cancer immunotherapy drug discovery outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the cancer immunotherapy drug discovery outsourcing industry. This cancer immunotherapy drug discovery outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cancer immunotherapy drug discovery outsourcing market includes revenues earned by entities by providing services such as preclinical testing, clinical trial support, and biomarker discovery. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The cancer immunotherapy drug discovery outsourcing market size has grown rapidly in recent years. It will grow from $1.5 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing cases of adverse drug reactions, increasing demand for comprehensive genomic testing, increasing global incidence of cancer, a growing need for targeted therapy, and a growing number of clinical trials.
The cancer immunotherapy drug discovery outsourcing market size is expected to see rapid growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to the rising importance of personalized medicine, increasing diagnostic tests, increasing focus on personalized cancer therapy, increasing healthcare expenditure, and increasing cancer incidence and awareness. Major trends in the forecast period include advancements in diagnostic technologies, next-generation sequencing (NGS), integration of artificial intelligence (AI), liquid biopsy technologies, the development of point-of-care companion diagnostic devices, and innovative testing technologies.
The escalating expenses associated with research and development (R&D) are projected to drive the expansion of the cancer immunotherapy drug discovery outsourcing market. The substantial R&D costs stem from the necessity of specialized expertise, costly equipment, and the inherent risks linked with innovation. The outsourcing of drug discovery activities taps into the economies of scale provided by contract research organizations (CROs), enabling smaller biotech firms and startups to optimize their R&D budgets and allocate resources more efficiently, thereby enhancing cost-effectiveness. For instance, in June 2023, as reported by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the total pharmaceutical R&D expenditure in Europe reached $49.5 billion (€44,500 million) in 2022, marking a rise of around 6.45% from $46.5 billion (€42,533 million) in 2021. Consequently, the exorbitant costs associated with in-house research and development are fueling the growth of the cancer immunotherapy drug discovery outsourcing market.
Key players in the cancer immunotherapy drug discovery outsourcing market are embracing a strategic partnership approach to bolster cancer drug production and gain competitive advantages. Strategic partnerships typically involve collaborative relationships among two or more organizations, pooling their resources, expertise, and efforts to achieve common goals or objectives. For instance, in February 2022, Ono Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, and Bristol-Myers Squibb, a US-based biopharmaceutical company, forged an outsourcing agreement with Prime Research Institute for Medical Research, Inc., a Japan-based research institute, for a joint clinical research project focused on gastric cancer patients treated with Opdivo (nivolumab) in combination with chemotherapy. This collaborative initiative, sponsored by the industry, encompasses a large-scale, multi-institutional study employing PRiME-R's CyberOncology data input support system, facilitating the standardization, structuring, management, and integration of real-world data in routine cancer clinical practice. The clinical research, utilizing CyberOncology, assesses the effectiveness of Opdivo combined with chemotherapy for untreated advanced or recurrent gastric cancer. Involving approximately 30 medical institutions nationwide, the study aims to streamline data input, improve data accuracy, and expedite analysis.
In February 2022, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, entered into a collaboration with Bristol Myers Squibb K.K., a US-based multinational biopharmaceutical company. The partnership aims to conduct a large-scale, multi-institutional clinical research study to assess the efficacy and safety of Opdivo (nivolumab) in combination with chemotherapy for patients with advanced or recurrent gastric cancer. This initiative makes use of PRIMER's CyberOncology system, which standardizes and integrates real-world data from clinical practice, enhancing the accuracy and efficiency of the research process.
Major companies operating in the cancer immunotherapy drug discovery outsourcing market are Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, WuXi AppTec Co Ltd., Charles River Laboratories International Inc., PerkinElmer Inc, Bio-Rad Laboratories Inc, QIAGEN N.V., Evotec SE, Shanghai ChemPartner Co. Ltd., Aragen Life Sciences Limited, GenScript Biotech Corporation, BGI Genomics Co. Ltd., NeoGenomics Laboratories Inc, ARUP Laboratories, Syngene International Limited, BioDuro-Sundia, Ambry Genetics Corporation, Selvita, Crown Bioscience International, CENTOGENE N.V., Jubilant Biosys, Oncodesign Services, Icagen Inc., Reaction Biology Corporation, ChemBridge Corporation.
North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer immunotherapy drug discovery outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cancer immunotherapy drug discovery outsourcing is a specialized service model within the pharmaceutical and biotech sectors. It involves entrusting aspects of cancer immunotherapy drug development to external service providers, typically contract research organizations (CROs) or contract development and manufacturing organizations (CDMOs). This approach accelerates innovation by leveraging external expertise and resources, allowing pharmaceutical companies to concentrate on their core activities.
The primary drug types involved in cancer immunotherapy drug discovery outsourcing include monoclonal antibodies, immunomodulators, oncolytic viral therapies, cancer vaccines, and others. Monoclonal antibodies are laboratory-made molecules that mimic the immune system's ability to target specific proteins on cancer cells, aiding in fighting off harmful pathogens. The services provided encompass target identification and validation, lead screening and characterization, and cell-based assays utilized in therapeutic areas such as lung cancer, breast cancer, melanoma, and others.
The cancer immunotherapy drug discovery outsourcing market research report is one of a series of new reports that provides cancer immunotherapy drug discovery outsourcing market statistics, including cancer immunotherapy drug discovery outsourcing industry global market size, regional shares, competitors with a cancer immunotherapy drug discovery outsourcing market share, detailed cancer immunotherapy drug discovery outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the cancer immunotherapy drug discovery outsourcing industry. This cancer immunotherapy drug discovery outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cancer immunotherapy drug discovery outsourcing market includes revenues earned by entities by providing services such as preclinical testing, clinical trial support, and biomarker discovery. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cancer Immunotherapy Drug Discovery Outsourcing Market Characteristics3. Cancer Immunotherapy Drug Discovery Outsourcing Market Trends and Strategies4. Cancer Immunotherapy Drug Discovery Outsourcing Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Cancer Immunotherapy Drug Discovery Outsourcing Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Cancer Immunotherapy Drug Discovery Outsourcing Market34. Recent Developments in the Cancer Immunotherapy Drug Discovery Outsourcing Market
5. Global Cancer Immunotherapy Drug Discovery Outsourcing Growth Analysis and Strategic Analysis Framework
6. Cancer Immunotherapy Drug Discovery Outsourcing Market Segmentation
7. Cancer Immunotherapy Drug Discovery Outsourcing Market Regional and Country Analysis
8. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market
9. China Cancer Immunotherapy Drug Discovery Outsourcing Market
10. India Cancer Immunotherapy Drug Discovery Outsourcing Market
11. Japan Cancer Immunotherapy Drug Discovery Outsourcing Market
12. Australia Cancer Immunotherapy Drug Discovery Outsourcing Market
13. Indonesia Cancer Immunotherapy Drug Discovery Outsourcing Market
14. South Korea Cancer Immunotherapy Drug Discovery Outsourcing Market
15. Western Europe Cancer Immunotherapy Drug Discovery Outsourcing Market
16. UK Cancer Immunotherapy Drug Discovery Outsourcing Market
17. Germany Cancer Immunotherapy Drug Discovery Outsourcing Market
18. France Cancer Immunotherapy Drug Discovery Outsourcing Market
19. Italy Cancer Immunotherapy Drug Discovery Outsourcing Market
20. Spain Cancer Immunotherapy Drug Discovery Outsourcing Market
21. Eastern Europe Cancer Immunotherapy Drug Discovery Outsourcing Market
22. Russia Cancer Immunotherapy Drug Discovery Outsourcing Market
23. North America Cancer Immunotherapy Drug Discovery Outsourcing Market
24. USA Cancer Immunotherapy Drug Discovery Outsourcing Market
25. Canada Cancer Immunotherapy Drug Discovery Outsourcing Market
26. South America Cancer Immunotherapy Drug Discovery Outsourcing Market
27. Brazil Cancer Immunotherapy Drug Discovery Outsourcing Market
28. Middle East Cancer Immunotherapy Drug Discovery Outsourcing Market
29. Africa Cancer Immunotherapy Drug Discovery Outsourcing Market
30. Cancer Immunotherapy Drug Discovery Outsourcing Market Competitive Landscape and Company Profiles
31. Cancer Immunotherapy Drug Discovery Outsourcing Market Other Major and Innovative Companies
35. Cancer Immunotherapy Drug Discovery Outsourcing Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Cancer Immunotherapy Drug Discovery Outsourcing Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cancer immunotherapy drug discovery outsourcing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cancer immunotherapy drug discovery outsourcing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer immunotherapy drug discovery outsourcing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Type: Monoclonal Antibodies; Immunomodulators; Oncolytic Viral Therapies and Cancer Vaccines; Other Drug Types2) By Service Type: Target Identification and Validation; Lead Screening and Characterization; Cell-Based Assays
3) By Therapeutic Area: Lung Cancer; Breast Cancer; Melanoma; Other Therapeutic Areas
Subsegments:
1) By Monoclonal Antibodies: Checkpoint Inhibitors; Therapeutic Monoclonal Antibodies; Bispecific Antibodies; Antibody-Drug Conjugates (ADCs)2) By Immunomodulators: Cytokines; Immune Checkpoint Modulators; Toll-Like Receptor Agonists; Immune Adjuvants
3) By Oncolytic Viral Therapies and Cancer Vaccines: Oncolytic Virus-Based Therapies; Cancer Vaccines; Viral Vectors for Immunotherapy
4) By Other Drug Types: Adoptive Cell Therapy; Immune Cell Modulators; Small Molecule Immune Modulators; Gene Editing and Immunotherapy
Key Companies Mentioned: Thermo Fisher Scientific Inc.; Danaher Corporation; Laboratory Corporation of America Holdings (LabCorp); Eurofins Scientific SE; WuXi AppTec Co Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Cancer Immunotherapy Drug Discovery Outsourcing market report include:- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Laboratory Corporation of America Holdings (LabCorp)
- Eurofins Scientific SE
- WuXi AppTec Co Ltd.
- Charles River Laboratories International Inc.
- PerkinElmer Inc
- Bio-Rad Laboratories Inc
- QIAGEN N.V.
- Evotec SE
- Shanghai ChemPartner Co. Ltd.
- Aragen Life Sciences Limited
- GenScript Biotech Corporation
- BGI Genomics Co. Ltd.
- NeoGenomics Laboratories Inc
- ARUP Laboratories
- Syngene International Limited
- BioDuro-Sundia
- Ambry Genetics Corporation
- Selvita
- Crown Bioscience International
- CENTOGENE N.V.
- Jubilant Biosys
- Oncodesign Services
- Icagen Inc.
- Reaction Biology Corporation
- ChemBridge Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | April 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 1.68 Billion |
Forecasted Market Value ( USD | $ 2.57 Billion |
Compound Annual Growth Rate | 11.3% |
Regions Covered | Global |
No. of Companies Mentioned | 27 |